Drug Profile


Alternative Names: 1303; EMAB-6; LFB-R603; R603; TG-1101; TG-1303; TGTX-1101; Utuxin

Latest Information Update: 13 Jan 2017

Price : $50

At a glance

  • Originator GTC Biotherapeutics; LFB Biotechnologies
  • Developer Johns Hopkins University; LFB Biotechnologies; TG Therapeutics Inc
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action CD20 antigen inhibitors; CD200 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Neuromyelitis optica; Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma; MALT lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Chronic lymphocytic leukaemia
  • Phase II Diffuse large B cell lymphoma; Mantle-cell lymphoma; Multiple sclerosis
  • Phase I/II Non-Hodgkin's lymphoma
  • Phase I Neuromyelitis optica

Most Recent Events

  • 13 Jan 2017 Efficacy data from a phase II trial in Multiple sclerosis released by TG Therapeutics
  • 11 Jan 2017 TG Therapeutics completes enrolment in its phase II trial for Multiple sclerosis (Monotherapy, Second-line therapy or greater) in USA (IV)
  • 09 Jan 2017 The US FDA grants Orphan Drug status for the combination of ublituximab and TGR-1202 for the treatment of Chronic lymphocytic leukaemia in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top